Abstract
Human papillomaviruses (HPVs) are a group of host-specific DNA viruses, with more than 120 different types identified to date. HPVs are classified as high- or low-risk (HR or LR) depending on their potential to induce cancer. Persistent infections with HR types of HPVs present a major risk factor for the development of a variety of human cancers including cervical, colorectal, head and neck as well as breast cancers. On the other hand, the deregulation of ErbB family tyrosine kinase receptors has also been associated with several types of human cancers. For instance, ErbB2 has been shown to have an important role in human carcinomas, specifically breast cancer. Moreover, the E-cadherin/catenin complex plays a pivotal role in the maintenance of normal adhesion in epithelial cells, and has been demonstrated to suppress tumor invasion and participate in cell signaling in human carcinomas. This review focuses on the interaction between HRHPV/ ErbB2 tyrosine receptors and the E-cadherin/catenin complex in human carcinomas including cervical, colorectal, head and neck and breast cancers.
Keywords: HPV, ErbB receptors, E-cadherin/catenin complex, cervical cancer, colorectal cancer, head and neck cancer and breast cancer
Current Pharmaceutical Design
Title: High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis
Volume: 14 Issue: 22
Author(s): Ala-Eddin Al Moustafa, Amal Kassab, Andrew Darnel and Amber Yasmeen
Affiliation:
Keywords: HPV, ErbB receptors, E-cadherin/catenin complex, cervical cancer, colorectal cancer, head and neck cancer and breast cancer
Abstract: Human papillomaviruses (HPVs) are a group of host-specific DNA viruses, with more than 120 different types identified to date. HPVs are classified as high- or low-risk (HR or LR) depending on their potential to induce cancer. Persistent infections with HR types of HPVs present a major risk factor for the development of a variety of human cancers including cervical, colorectal, head and neck as well as breast cancers. On the other hand, the deregulation of ErbB family tyrosine kinase receptors has also been associated with several types of human cancers. For instance, ErbB2 has been shown to have an important role in human carcinomas, specifically breast cancer. Moreover, the E-cadherin/catenin complex plays a pivotal role in the maintenance of normal adhesion in epithelial cells, and has been demonstrated to suppress tumor invasion and participate in cell signaling in human carcinomas. This review focuses on the interaction between HRHPV/ ErbB2 tyrosine receptors and the E-cadherin/catenin complex in human carcinomas including cervical, colorectal, head and neck and breast cancers.
Export Options
About this article
Cite this article as:
Al Moustafa Ala-Eddin, Kassab Amal, Darnel Andrew and Yasmeen Amber, High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis, Current Pharmaceutical Design 2008; 14 (22) . https://dx.doi.org/10.2174/138161208785740216
DOI https://dx.doi.org/10.2174/138161208785740216 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HR MAS MR Spectroscopy in Metabolic Characterization of Cancer
Current Topics in Medicinal Chemistry Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas
Current Cancer Drug Targets Analysis of Edg-Like LPA Receptor-Ligand Interactions
Current Pharmaceutical Design Nardilysin, A Basic Residues Specific Metallopeptidase That Mediates Cell Migration and Proliferation
Protein & Peptide Letters Formulation Development of Folic Acid Conjugated PLGA Nanoparticles for Improved Cytotoxicity of Caffeic Acid Phenethyl Ester
Pharmaceutical Nanotechnology p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations - Part 1
Current Medicinal Chemistry Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract
Current Pharmaceutical Design Neuropeptide Mimetics and Antagonists in the Treatment of Inflammatory Disease: Focus on VIP and PACAP
Current Topics in Medicinal Chemistry Aptamer-Based Targeted Drug Delivery Systems: Current Potential and Challenges
Current Medicinal Chemistry In Vivo Beta-Cell Imaging with VMAT 2 Ligands - Current State-of-the-Art and Future Perspectives
Current Pharmaceutical Design ADAM9 as a Potential Target Molecule in Cancer
Current Pharmaceutical Design Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design Nanoparticle-based Cerebral Drug-Delivery Systems and Antiangiogenic Approach in Gliomas Treatment
Recent Patents on Nanotechnology Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 1 – Where Do We Stand?
Clinical Cancer Drugs Systemic Therapies for Pancreatic Cancer - The Role of Pharmacogenetics
Current Drug Targets Perspectives on Medicinal Properties of Mangiferin
Mini-Reviews in Medicinal Chemistry Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets